Alpha Tau Net Income Over Time
| DRTS Stock | USD 7.93 0.49 5.82% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alpha Tau Performance and Alpha Tau Correlation. Is there potential for Biotechnology market expansion? Will Alpha introduce new products? Factors like these will boost the valuation of Alpha Tau. Projected growth potential of Alpha fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Alpha Tau listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alpha Tau Medical is measured differently than its book value, which is the value of Alpha that is recorded on the company's balance sheet. Investors also form their own opinion of Alpha Tau's value that differs from its market value or its book value, called intrinsic value, which is Alpha Tau's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Alpha Tau's market value can be influenced by many factors that don't directly affect Alpha Tau's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Alpha Tau's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Alpha Tau should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Alpha Tau's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Alpha Tau Medical and related stocks such as Cellectis SA, Alto Neuroscience, and Genelux Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLLS | (4.4 M) | (30.9 M) | (29.5 M) | (84.3 M) | 24.3 K | (22.5 M) | (63.9 M) | (99.4 M) | (78.7 M) | (90.7 M) | (72.6 M) | (86.3 M) | (98.7 M) | (101.1 M) | (36.8 M) | (33.1 M) | (34.7 M) |
| ANRO | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (27.7 M) | (36.3 M) | (61.4 M) | (61.4 M) | (55.3 M) | (52.5 M) |
| GNLX | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (14.9 M) | (17.8 M) | (5.2 M) | (28.3 M) | (29.9 M) | (26.9 M) | (28.2 M) |
| LRMR | (13.2 M) | (13.2 M) | (13.9 M) | (14 M) | (36.6 M) | (74.3 M) | (57.9 M) | (52 M) | (61.4 M) | (23.1 M) | (42.3 M) | (50.3 M) | (34.2 M) | (36.9 M) | (80.6 M) | (72.5 M) | (68.9 M) |
| ACIU | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | 10.7 M | 20.3 M | (7.1 M) | (26.4 M) | (51 M) | 45.4 M | (61.9 M) | (73 M) | (70.8 M) | (54.2 M) | (50.9 M) | (45.8 M) | (43.5 M) |
| DMAC | (640 K) | (6.6 M) | (10.1 M) | (7.4 M) | (4.8 M) | (1.4 M) | (2.2 M) | (4.3 M) | (5.7 M) | (10.6 M) | (12.3 M) | (13.6 M) | (13.7 M) | (19.4 M) | (24.4 M) | (22 M) | (20.9 M) |
| AMRN | 900 K | (69.4 M) | (179.2 M) | (166.2 M) | (56.4 M) | (115.2 M) | (86.3 M) | (67.9 M) | (116.4 M) | (22.6 M) | (18 M) | 7.7 M | (105.8 M) | (59.1 M) | (82.2 M) | (38.8 M) | (40.7 M) |
| ALDX | (2.4 M) | (2.4 M) | (23.1 M) | 13.1 M | (5.2 M) | (12.1 M) | (18.7 M) | (22.3 M) | (38.9 M) | (60.8 M) | (37.6 M) | (57.8 M) | (62 M) | (37.5 M) | (55.9 M) | (50.3 M) | (47.8 M) |
| DBVT | (6.1 M) | (9.4 M) | (17 M) | (26.6 M) | (29.1 M) | (48.5 M) | (126.3 M) | (177.2 M) | (190.3 M) | (172 M) | (159.6 M) | (97.8 M) | (96.3 M) | (72.7 M) | (113.7 M) | (102.3 M) | (107.5 M) |
| CADL | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (17.7 M) | (36.1 M) | (18.8 M) | (37.9 M) | (55.2 M) | (49.7 M) | (47.2 M) |
Alpha Tau Medical and related stocks such as Cellectis SA, Alto Neuroscience, and Genelux Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Alpha Tau Medical financial statement analysis. It represents the amount of money remaining after all of Alpha Tau Medical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Alpha Tau Medical | DRTS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Kiryat HaMada St |
| Exchange | NASDAQ Exchange |
USD 7.93
Additional Tools for Alpha Stock Analysis
When running Alpha Tau's price analysis, check to measure Alpha Tau's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alpha Tau is operating at the current time. Most of Alpha Tau's value examination focuses on studying past and present price action to predict the probability of Alpha Tau's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alpha Tau's price. Additionally, you may evaluate how the addition of Alpha Tau to your portfolios can decrease your overall portfolio volatility.